Enter the set! Koren's another heavy injection was the first!

Drug Basics Moxix, developed by Bayer of Germany, was launched in China in September 1999 and in the United States in December of that year under the name Avelox.
2002, Moxisha Xing was approved to enter the Chinese market, the product is called "Bay Fule".
Moxixa is a fourth-generation quinone antibiotic, known as "respiratory quinoxone" together with LOX (third generation) and Jimi sassin (fourth generation), and is particularly effective against Streptococcus pneumoniae, which is currently highly resistant.
new drug research and development monitoring database (CPM) shows that in China's Moxiza star mainly oral regular release agents, injections and eye drops three dosage forms, and are health insurance varieties.
Plus oral regular release and injection have been included in the national collection range.
, Tianjin Red Day and Hainan Aike both passed the consistent evaluation with 4 categories of declarations, and won the bid with 32.8 yuan and 35.27 yuan, respectively.
Sodium chloride injection of hydrochloric acid has now become a first-line drug for multi-departmental anti-infection treatment, widely used in respiratory, intensive care wards, surgery, emergency departments, etc., has been "antimicrobial drug clinical application guidelines (2015)," "adult community access to pneumonia primary diagnosis and treatment guidelines (2018)" and other domestic authoritative guidelines recommended.
Comprehensive Drug Database (PDB) shows that in China's sample hospitals, Moxisas injection form dominates, with a market share of 85%.
market for injections showed relatively rapid growth, with a compound growth rate of more than 16%.
, Nanjing Yuke's domestic replacement is strong.
, however, the future market pattern is expected to change dramaticly due to the failure of the Nanjing Yukomosishin injection due to failure to pass the consistency evaluation.
PDB drug comprehensive database and with the columin hydrochloric acid moxisa star sodium chloride injection in the domestic same variety of the first injection consistency evaluation channel through the consistent evaluation, or will enhance the variety in the selected enterprises on the basis of the remaining market competitiveness, for the next collection to do a full preparation.
。